See Emily, Ethier Isabelle, Cho Yeoungjee, Htay Htay, Arruebo Silvia, Caskey Fergus J, Damster Sandrine, Donner Jo-Ann, Jha Vivekanand, Levin Adeera, Nangaku Masaomi, Saad Syed, Tonelli Marcello, Ye Feng, Okpechi Ikechi G, Bello Aminu K, Johnson David W
Department of Nephrology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Department of Nephrology, Royal Children's Hospital, Parkville, Victoria, Australia.
Kidney Int Rep. 2024 May 23;9(8):2410-2419. doi: 10.1016/j.ekir.2024.05.014. eCollection 2024 Aug.
Kidney failure treated with hemodialysis (HD), or peritoneal dialysis (PD) is a major global health problem that is associated with increased risks of death and hospitalization. This study aimed to compare the incidence and causes of death and hospitalization during the first year of HD or PD among countries.
The third iteration of the International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA) was conducted between June and September 2022. For this analysis, data were obtained from the cross-sectional survey of key stakeholders from ISN-affiliated countries.
A total of 167 countries participated in the survey (response rate 87.4%). In 48% and 58% of countries, 1% to 10% of people treated with HD and PD died within the first year, respectively, with cardiovascular disease being the main cause. Access-related infections or treatment withdrawal owing to cost were important causes of death in low-income countries (LICs). In most countries, <30% and <20% of patients with HD and PD, respectively, required hospitalization during the first year. A greater proportion of patients with HD and PD in LICs were hospitalized in the first year than those in high-income countries (HICs). Access-related infection and cardiovascular disease were the commonest causes of hospitalization among patients with HD, whereas PD-related infection was the commonest cause in patients with PD.
There is significant heterogeneity in the incidence and causes of death and hospitalization in patients with kidney failure treated with dialysis. These findings highlight opportunities to improve care, especially in LICs where infectious and social factors are strong contributors to adverse outcomes.
采用血液透析(HD)或腹膜透析(PD)治疗的肾衰竭是一个重大的全球健康问题,与死亡和住院风险增加相关。本研究旨在比较各国HD或PD治疗第一年期间的死亡和住院发生率及原因。
国际肾脏病学会全球肾脏健康地图集(ISN-GKHA)的第三次迭代于2022年6月至9月进行。对于本分析,数据来自对ISN附属国家关键利益相关者的横断面调查。
共有167个国家参与了调查(回复率87.4%)。在48%和58%的国家中,接受HD和PD治疗的患者分别有1%至10%在第一年内死亡,主要原因是心血管疾病。在低收入国家(LICs),与通路相关的感染或因费用问题停止治疗是重要的死亡原因。在大多数国家,接受HD和PD治疗的患者在第一年内分别有<30%和<20%需要住院治疗。LICs中接受HD和PD治疗的患者在第一年内住院的比例高于高收入国家(HICs)。与通路相关的感染和心血管疾病是HD患者住院最常见的原因,而与PD相关的感染是PD患者住院最常见的原因。
接受透析治疗的肾衰竭患者在死亡和住院发生率及原因方面存在显著异质性。这些发现凸显了改善护理的机会,尤其是在低收入国家,感染和社会因素是不良结局的重要促成因素。